November 21, 2014
Kissei Pharmaceutical has filed a new drug application (NDA) in Japan for its hyperphosphatemia treatment PA21 (development code), it said on November 19. The proposed indication is for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis. The...read more